The Immunotherapy stream focuses on the latest protein engineering strategies, emerging modalities and clinical data driving the development of immunotherapies for cancer and immune disorders. Part One examines the tumor microenvironment, target identification, improving efficacy and safety, and emerging cell-based therapies such as NK cells and gamma deltas. Part Two focuses on developing and engineering adoptive cell therapies for solid and liquid tumors, especially CAR Ts, TCRs, NKs, and TILs, as well as new targets of interest. Part Three examines new clinical and preclinical data in agonist immunotherapy targets, as well as the biology and mechanisms of these emerging therapies of interest. Together, these three units will provide a focused look at how industry is applying new science and technology in developing the next generation of targeted cancer immunotherapies.
Prasad Adusumilli, MD, FACS, FCCPDeputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma
Adrian Bot, PhD Vice President, Translational Medicine, Kite Pharma, a Gilead Company
Axel Hoos, PhD Senior Vice President, Therapeutic Area Head, Oncology, GSK
Jeffrey Miller, MD Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota